Skip to main content
    A

    Anika Therapeutics Inc (ANIK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $12.92
    -0.48 (-3.58%)

    Market Cap: $179.50M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anika Therapeutics Inc (ANIK) Earnings: Report Dates and Results

    Updated Nov 6, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Anika Therapeutics (ANIK) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Anika Therapeutics reported EPS of -$0.01, below the $0.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +44.61%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range$0.00 - $0.01
    4 analysts
    Revenue Consensus
    $30.32M
    Range$29.06M - $31.29M
    4 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.05
    Range$0.05 - $0.05
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.02+433.3%
    60d ago-$0.02+433.3%
    30d ago$0.06-9.1%
    7d ago$0.06-9.1%
    Current$0.05
    Revenue Consensus
    $30.11M
    Range$30.10M - $30.13M
    2 analysts

    Next Report

    ANIK has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 92.3% below the $0.13 reported for the quarter ended Dec 31, 2025.

    ANIK Earnings Call

    The latest ANIK earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, ANIK beat 23, missed 14 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $30.59M, up 10.0% from $27.82M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.01$0.02N/A-150.00%MissN/A11 up, 0 downNov 6, 2026$30.59M
    Jun 30, 2026$0.30-$0.19N/A+257.89%BeatN/A10 up, 1 downJul 29, 2026$32.61M
    Mar 31, 2026$0.27-$0.16N/A+268.75%BeatN/A10 up, 1 downApr 29, 2026$29.61M
    Dec 31, 2025$0.13-$0.19N/A+168.42%BeatN/A10 up, 1 downFeb 26, 2026$30.61M
    Sep 30, 2025-$0.17-$0.19N/A+10.53%BeatN/A10 up, 1 downNov 5, 2025$27.82M
    Jun 30, 2025-$0.13-$0.13-$0.13 - -$0.130.00%In line-176.5%10 up, 1 downJul 30, 2025$28.22M
    Mar 31, 2025-$0.06$0.09$0.09 - $0.09-166.67%Miss-166.7%10 up, 1 downMay 9, 2025$26.17M
    Dec 31, 2024-$0.14-$0.11N/A-27.27%MissN/A11 up, 1 downMar 12, 2025$30.60M
    Sep 30, 2024-$0.25$0.30N/A-183.33%MissN/A20 up, 0 downOct 31, 2024$29.56M
    Jun 30, 2024$0.17$0.20N/A-15.00%Miss+183.3%30 up, 0 downAug 8, 2024$30.72M
    Mar 31, 2024$0.09$0.05N/A+80.00%BeatN/A30 up, 1 downMay 8, 2024$29.02M
    Dec 31, 2023-$4.30-$0.26-$0.32 - -$0.21N/AN/AN/A30 up, 0 downMar 13, 2024N/A
    Sep 30, 2023-$0.45-$0.35-$0.43 - -$0.33-28.57%MissN/A30 up, 0 downNov 2, 2023$41.47M
    Jun 30, 2023$0.06-$0.32N/A+118.75%BeatN/A20 up, 0 downAug 8, 2023$44.30M
    Mar 31, 2023-$0.36-$0.32-$0.36 - -$0.25-12.50%MissN/A30 up, 0 downMay 9, 2023$37.92M
    Dec 31, 2022-$0.34-$0.24-$0.30 - -$0.20-41.67%MissN/A30 up, 0 downMar 6, 2023N/A
    Sep 30, 2022-$0.05-$0.23N/A+78.26%Beat-200.0%30 up, 0 downNov 8, 2022$40.26M
    Jun 30, 2022-$0.12-$0.21-$0.31 - -$0.11+42.86%Beat-233.3%30 up, 0 downAug 3, 2022$39.66M
    Mar 31, 2022-$0.11-$0.31-$0.42 - -$0.31+64.52%Beat-283.3%20 up, 0 downMay 5, 2022$36.69M
    Dec 31, 2021-$0.40-$0.25-$0.34 - -$0.16-60.00%Miss-433.3%41 up, 0 downMar 8, 2022$35.82M
    Sep 30, 2021$0.05$0.05N/A0.00%In line0.0%3N/ANov 4, 2021$39.54M
    Jun 30, 2021$0.09-$0.03N/A+400.00%Beat0.0%3N/AAug 5, 2021$38.15M
    Mar 31, 2021$0.06$0.01N/A+500.00%Beat-86.7%2N/AMay 6, 2021$34.29M
    Dec 31, 2020$0.12$0.14N/A-14.29%Miss-72.1%2N/AMar 4, 2021$32.69M
    Sep 30, 2020$0.05$0.13-$0.15 - $0.13-61.54%Miss-92.2%2N/ANov 4, 2020$31.69M
    Jun 30, 2020$0.09-$0.14-$0.42 - -$0.07+164.29%Beat-86.6%2N/AJul 30, 2020$30.68M
    Mar 31, 2020$0.45$0.22N/A+104.55%Beat+45.2%2N/AMay 7, 2020$35.40M
    Dec 31, 2019$0.43$0.42$0.38 - $0.44+2.38%Beat-20.4%3N/AFeb 20, 2020$29.77M
    Sep 30, 2019$0.64$0.39$0.37 - $0.42+64.10%Beat+20.8%3N/AOct 24, 2019$29.70M
    Jun 30, 2019$0.67$0.40$0.36 - $0.43+67.50%Beat-1.5%4N/AJul 24, 2019$30.42M
    Mar 31, 2019$0.31$0.20$0.15 - $0.24+55.00%BeatN/A4N/AMay 2, 2019$24.72M
    Dec 31, 2018$0.54$0.33$0.25 - $0.39+63.64%Beat+42.1%4N/AFeb 21, 2019$26.96M
    Sep 30, 2018$0.53$0.31$0.27 - $0.35+70.97%Beat+15.2%4N/AOct 24, 2018$26.79M
    Jun 30, 2018$0.68$0.29$0.27 - $0.44+134.48%Beat-10.5%4N/AJul 25, 2018$30.55M
    Mar 31, 2018-$0.46$0.25-$0.14 - $0.26-284.00%Miss-224.3%4N/AMay 2, 2018$21.26M
    Dec 31, 2017$0.38$0.44$0.37 - $0.48-13.64%Miss-29.6%4N/AFeb 21, 2018$29.39M
    Sep 30, 2017$0.46$0.42$0.42 - $0.51+9.52%Beat-22.0%2N/AOct 25, 2017$27.18M
    Jun 30, 2017$0.76$0.44$0.42 - $0.47+72.73%Beat+33.3%3N/AJul 26, 2017$33.46M
    Mar 31, 2017$0.37$0.38N/A-2.63%Miss-17.8%N/AN/AMay 3, 2017$23.39M
    Dec 31, 2016$0.54$0.53N/A+1.89%Beat-25.0%N/AN/AFeb 15, 2017$28.73M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.23, after -$0.13 the year before. It was $2.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.23N/A
    Dec 31, 2024-$0.13N/A
    Dec 31, 2023-$5.05N/A
    Dec 31, 2022-$0.62N/A
    Dec 31, 2021-$0.20-128.2%
    Dec 31, 2020$0.71-65.4%
    Dec 31, 2019$2.05+58.9%
    Dec 31, 2018$1.29-34.5%
    Dec 31, 2017$1.97-8.4%
    Dec 31, 2016$2.15N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,0136
    2026Q2Jun 30, 20264,9956
    2026Q1Mar 31, 20264,4866
    2025Q4Dec 31, 20255,1246
    2025Q3Sep 30, 20254,1355
    2025Q2Jun 30, 20255,2027
    2025Q1Mar 31, 20255,5107
    2024Q4Dec 31, 20244,4886

    2026Q3 Earnings Call

    Opening remarks

    Matthew Hall Executive Director of Corporate Development and Investor Relations Good morning. Thank you for joining us for Anika's third quarter 2026 earnings call. I am Matthew Hall, Anika's Executive Director of Corporate Development and Investor Relations. Our earnings press release was issued earlier this morning and is available on our Investor Relations website, as are our supplementary PowerPoint slides that will be used for discussion today. With me on the call are Steve Griffin, President and Chief Executive Officer, and Ian W. McLeod, Senior Vice President, Chief Accounting Officer, and Treasurer. They will present our third quarter 2026 financial results and business highlights. Please take a moment to open the slide presentation and refer to slide 2. Before we begin, please understand that certain statements made during the call today constitute forward-looking statements as defined in the Securities Exchange Act of 1934. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results, performance, or achievements. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. Please also see our most recent SEC filings for more information about risks that could affect our performance. In addition, during the call, we may refer to several adjusted or non-GAAP financial measures, which may include adjusted gross margin, adjusted EBITDA, adjusted net income from continuing operations, and adjusted earnings per share from continuing operations. These are used in addition to results presented in accordance with GAAP financial measures. We believe that non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with GAAP financial measures and the reconciliation of GAAP measures, they provide an even more complete understanding of our business. A reconciliation of these adjusted non-GAAP financial results to the most comparable GAAP measurements is available at the end of the presentation slide deck and in our third quarter 2026 press release. With that, I will turn the call over to Steve to discuss the quarter and our progress. Steve?

    Stephen D. Griffin President and Chief Executive Officer Good morning, everyone, and thank you for joining us. Our third quarter performance marked another positive step in building a stronger, more profitable Anika. Revenue grew 10%, with growth in both our commercial and OEM channels. We improved gross margin year over year, expanded adoption of Integrity, completed key manufacturing and pipeline milestones, and strengthened a long-term partnership that will contribute to future growth. These results also reinforce the strategic focus we have built around our core hyaluronic acid platform and the opportunities it creates across our business.

    Frequently Asked Questions About ANIK

    When is Anika Therapeutics's next earnings date?

    Anika Therapeutics's next earnings report is expected for Feb 24, 2027.

    Did ANIK beat earnings estimates last quarter?

    No. Anika Therapeutics reported EPS of -$0.01 for the quarter ended Sep 30, 2026, below the $0.02 estimate by 150.00%.

    What EPS do analysts expect from ANIK next quarter?

    The consensus EPS estimate for Anika Therapeutics for the quarter ending Dec 31, 2026 is $0.01 from 4 analysts, with estimates from $0.00 to $0.01.

    How often does ANIK beat earnings estimates?

    Anika Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +45.21%.